Tirofiban After Tenecteplase in Stroke - Summary - MDSpire
From the Journals
Conference News

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was associated with higher rates of excellent 90-day outcomes after inadequate tenecteplase response in selected stroke patients, though adjusted analyses were not significant.

  • By

  • Kathryn Wighton

  • May 14, 2026

  • 6 min

Share

In the INSTANT randomized clinical trial published in JAMA, researchers found that patients with acute ischemic stroke who showed insufficient early responses to tenecteplase experienced improved functional outcomes at 90 days when treated with adjunctive intravenous tirofiban instead of placebo. The trial involved 359 patients in China and demonstrated a higher rate of excellent outcomes (64% vs. 52%) with tirofiban, though the adjusted analysis lacked significance. The study underscores tirofiban's potential as an adjunctive treatment, particularly for specific patient groups, while also noting constraints regarding generalizability and treatment timing.

Original Source(s)

Tirofiban After Tenecteplase in Stroke

  • by Kathryn Wighton

  • May 14, 2026

Related Content

Tenecteplase Prior to EVT Did Not Improve Stroke Outcomes

Phase 3 trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

The Chronic Disease Conundrum

Russ Lebovitz and Arnon Chait on why we need smarter biomarkers to guide clinically actionable diagnostics in an aging population

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.